文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌超低分次放疗对比中度低分次及常规分次放疗中选择性盆腔淋巴结照射:3项前瞻性临床试验结果

Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-08-16

2011至2019年开展的3项前瞻性临床试验共纳入240例不良中危或高危前列腺癌患者,分别接受常规分次放疗(CFRT)、中度低分次放疗(MHRT)或超低分次放疗(UHRT)联合选择性盆腔淋巴结照射(ENI)。中位随访71.6个月,5年生化失败累积发生率三组间无显著差异(p=0.38);UHRT组急性≥2级泌尿生殖毒性显著劣于CFRT和MHRT,但晚期毒性无差异。

要点

  • 接受ENI的UHRT与CFRT联合前列腺CFRT/MHRT的肿瘤学结局相似。
  • UHRT组急性≥2级泌尿生殖毒性显著劣于CFRT和MHRT组。
  • UHRT与晚期毒性恶化无关,三组5年生化失败无显著差异(p=0.38)。

核心结论

  • 采用UHRT进行ENI的肿瘤学结局与前列腺CFRT/MHRT联合CFRT ENI相似,急性≥2级泌尿生殖毒性更差但晚期毒性无差异。
  • 作者表示期待采用UHRT技术的ENI随机3期试验。

研究设计与样本

  • 2011至2019年间开展3项前瞻性临床试验,纳入不良中危或高危前列腺癌患者240例。
  • CFRT组90例(37.5%):前列腺78 Gy分39次,盆腔46 Gy分23次。
  • MHRT组90例(37.5%):前列腺68 Gy分25次,盆腔48 Gy。
  • UHRT组60例(25%):前列腺35-40 Gy分5次,前列腺内病灶加量至50 Gy,盆腔25 Gy。
  • 主要终点包括生化失败(Phoenix定义)及急性和晚期毒性(CTCAE v3.0/4.0)。

主要发现

  • 中位随访时间71.6个月(IQR 53.6-94.8)。
  • 5年生化失败累积发生率(95%CI):CFRT组11.7%(3.5-19.8%),MHRT组6.5%(0.8-12.2%),UHRT组1.8%(0-5.2%),三组间无显著差异(p=0.38)。
  • UHRT组急性≥2级泌尿生殖毒性显著劣于CFRT和MHRT组。
  • 急性≥3级泌尿生殖毒性及急性胃肠道毒性三组间无显著差异。
  • UHRT与晚期毒性恶化无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Data is needed regarding the use of ultrahypofractionated radiotherapy (UHRT) in the context of prostate cancer elective nodal irradiation (ENI), and how this compares to conventionally fractionated radiotherapy (CFRT) ENI with CFRT or moderately hypofractionated radiotherapy (MHRT) to the prostate. MATERIALS AND METHODS: Between 2011-2019, 3 prospective clinical trials of unfavourable intermediate or high-risk prostate cancer receiving CFRT (78 Gy in 39 fractions to prostate; 46 Gy in 23 fractions to pelvis), MHRT (68 Gy in 25 fractions to prostate; 48 Gy to pelvis), or UHRT (35-40 Gy in 5 fractions to prostate +/- boost to 50 Gy to intraprostatic lesion; 25 Gy to pelvis) were conducted. Primary endpoints included biochemical failure (Phoenix definition), and acute and late toxicities (CTCAE v3.0/4.0). RESULTS: Two-hundred-forty patients were enrolled: 90 (37.5 %) had CFRT, 90 (37.5 %) MHRT, and 60 (25 %) UHRT. Median follow-up time was 71.6 months (IQR 53.6-94.8). Cumulative incidence of biochemical failure (95 % CI) at 5-years was 11.7 % (3.5-19.8 %) for CFRT, 6.5 % (0.8-12.2 %) MHRT, and 1.8 % (0-5.2 %) UHRT, which was not significantly different between treatments (p = 0.38). Acute grade ≥ 2 genitourinary toxicity was significantly worse for UHRT versus CFRT and MHRT, but not for acute grade ≥ 3 genitourinary, or acute gastrointestinal toxicities. UHRT was not associated with worse late toxicities. CONCLUSION: ENI with UHRT resulted in similar oncologic outcomes to CFRT ENI with prostate CFRT/MHRT, with worse acute grade ≥ 2 GU toxicity but no differences in late toxicity. Randomized phase 3 trials of ENI using UHRT techniques are much anticipated.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Glicksman RM, Loblaw A, Morton G, et al. Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials. Clin Transl Radiat Oncol. 2024. PMID: 39318680. doi:10.1016/j.ctro.2024.100843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。